DelveInsight’s, “HER2 Positive Breast Cancer Pipeline Insight 2023” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including HER2 Positive Breast Cancer clinical trials and nonclinical stage products. It also covers the HER2 Positive Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the HER2 Positive Breast Cancer Pipeline Report
Discover the recent advances in HER2-positive breast cancer treatment drugs @ HER2-Positive Breast Cancer Pipeline Outlook
Recent Developmental Activities in the HER2-Positive Breast Cancer Treatment Landscape
HER2-Positive Breast Cancer Overview
HER2-positive breast cancer is when breast cancer cells have a protein receptor called HER2 (human epidermal growth factor receptor 2). Normally, this protein helps breast cells grow, divide, and repair themselves. But sometimes, something goes wrong in the gene that controls the HER2 protein and the body makes too many of these receptors. This causes the breast cells to grow and divide uncontrollably. About 1 of 5 breast cancers are HER2-positive.While HER2 is more aggressive than other types of breast cancer, there are treatments that can help. A lump in the breast that feels different from the area around it is the most common symptom of breast cancer. Other symptoms of HER2-positive breast cancer can include: Breast swelling, a change in its shape, skin irritation or dimpling, pain in the breast or nipple, redness or thickness of the nipple or breast skin and discharge from the nipple (not breast milk).
Find out more about HER2-positive breast cancer Treatment Drugs and HER2-positive breast cancer Companies @ HER2-Positive Breast Cancer Treatment Landscape
HER2 Positive Breast Cancer Emerging Drugs
ALT P7: Alteogen
Alteogen is using NexMab™ ADC technology to develop ALT-P7, a targeted breast / gastric cancer drug. ALT-P7 is an anti-HER2 targeting ADC utilizing NexMab™ ADC technology. ALT-P7’s payload drugs are site specifically conjugated to the HER2 targeted antibody, whereas Kadcyla has drug payloads conjugated, on a non-site specific manner, to the HER2 targeted antibody. Because of the site-specific conjugation, ALT-P7 can be developed as safer and better alternative anti-cancer drug than Kadcyla. A phase I clinical trial is being completed and phase II clinical trial will soon be held.
ARX 788: Ambrx
ARX788, is an anti-HER2 ADC currently being studied broadly in breast cancer, gastric/GEJ cancer and other solid tumor clinical trials. The United States Food and Drug Administration (FDA) has granted Fast Track Designation for ARX788 in HER2+ metastatic breast cancer and Orphan Drug Designation for ARX788 in gastric cancer. ARX788 is a homogeneous and highly stable ADC, which targets the HER2 receptor and contains two AS269 cytotoxic payloads site-specifically conjugated to a trastuzumab-based antibody. ARX788 was designed to maximize potential anti-tumor activity by optimizing the number and position of the payloads and the chemical bonds that conjugate the payloads to the antibody. Currently the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of HER2-positive Breast Cancer.
Inavolisib: Genentech
Inavolisib (GDC-0077, RG6114) is a small molecule PI3 kinase (PI3K) inhibitor. Dysregulation of PI3K signaling is implicated in a broad range of human cancers and activating mutations in the PI3K alpha-isoform gene (PIK3CA) are common oncogenic drivers. The PI3K/Akt/mTOR pathway regulates cell growth and survival. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of HER2-positive Breast Cancer.
HER2 Positive Breast Cancer Therapeutic Assessment
There are approx. 75+ key companies which are developing the therapies for HER2 Positive Breast Cancer. The companies which have their HER2 Positive Breast Cancer drug candidates in the most advanced stage, i.e. phase II /III include, Ambrx.
Learn more about the emerging new drug for HER2-positive breast cancer @ HER2-Positive Breast Cancer Ongoing Clinical Trials Analysis
Scope of the HER2-Positive Breast Cancer Pipeline Report
Table of Content
Key Questions
Current Treatment Scenario and Emerging Therapies:
Dive deep into rich insights for new drugs for HER2-positive breast cancer Emerging Drugs, visit @ HER2-Positive Breast Cancer Key Players and Pipeline Therapies
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/